Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis.
OBJECTIVE
Extensive studies have investigated the prognostic value of CD56 for patients with acute myeloid leukemia (AML), but the results remained inconclusive. The aim of this meta-analysis is to resolve this controversial issue.


METHODS
A systematic search of PubMed, Embase, Cochrane Library, and CBM was performed to identify studies that assessed the prognostic value of CD56 in AML patients. Pooled hazard ratios (HRs) with 95 % confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS) and pooled odds ratio (OR) with 95 % CIs for complete remission rate (CRR) and relapse rate (RR) were calculated.


RESULTS
Totally, 32 studies with 4074 patients were included. For AML with t(8;21) translocation, CD56 overexpression was associated with shorter OS (HR 2.22; 95 % CI 1.30-3.78) and DFS (HR 2.63; 95 % CI 1.10-6.29) and increased RR (OR 3.29; 95 % CI 1.67-6.48), but did not affect CRR (OR 0.94; 95 % CI 0.49-1.80). For AML with t(15;17) translocation, CD56 overexpression was associated with shorter OS (HR 2.43; 95 % CI 1.66-3.57) and DFS (HR 4.27; 95 % CI 1.15-15.78), increased RR (OR 3.11; 95 % CI 2.01-4.81), and decreased CRR (OR 0.42; 95 % CI 0.25-0.72). For AML as a whole, CD56 overexpression was associated with shorter OS (HR 1.74; 95 % CI 1.38-2.19) and DFS (HR 2.38; 95 % CI 1.87-3.02), increased RR (OR 5.19; 95 % CI 2.84-9.48), and decreased CRR (OR 0.62; 95 % CI 0.41-0.96).


CONCLUSIONS
This meta-analysis indicated that CD56 overexpression may be an adverse prognostic factor for AML.
Center for Hematology, Southwest Hospital, Third Military Medical University, Chongqing, China.
Shuangnian
S
Xu
Xi
X
Li
Jianmin
J
Zhang
Jieping
J
Chen
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019002:CD56 Antigen / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction / Q000379:methods; D014178:Translocation, Genetic / Q000502:physiology; D055815:Young Adult
D019002:CD56 Antigen; C522918:NCAM1 protein, human